Abstract
Summary
A drug used to treat mental illness caused by diabetes
LPI (LP Information)' newest research report, the “Diabetic Neurological Disorder Therapeutic Drug Industry Forecast” looks at past sales and reviews total world Diabetic Neurological Disorder Therapeutic Drug sales in 2022, providing a comprehensive analysis by region and market sector of projected Diabetic Neurological Disorder Therapeutic Drug sales for 2023 through 2029. With Diabetic Neurological Disorder Therapeutic Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Diabetic Neurological Disorder Therapeutic Drug industry.
This Insight Report provides a comprehensive analysis of the global Diabetic Neurological Disorder Therapeutic Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Diabetic Neurological Disorder Therapeutic Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Diabetic Neurological Disorder Therapeutic Drug market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Diabetic Neurological Disorder Therapeutic Drug and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Diabetic Neurological Disorder Therapeutic Drug.
The global Diabetic Neurological Disorder Therapeutic Drug market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Diabetic Neurological Disorder Therapeutic Drug is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Diabetic Neurological Disorder Therapeutic Drug is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Diabetic Neurological Disorder Therapeutic Drug is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Diabetic Neurological Disorder Therapeutic Drug players cover AstraZeneca, Johnson & Johnson, Takeda, Mitsubishi Chemical, Avanir Pharmaceuticals, Dong-A Pharmaceutical Co., Ltd., Immune Pharmaceuticals, MediciNova and Sangamo BioSciences, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Diabetic Neurological Disorder Therapeutic Drug market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Capsule
Pills
Other
Segmentation by application
Symmetrical Neuropathy
Focal and Multifocal Neuropathy
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
AstraZeneca
Johnson & Johnson
Takeda
Mitsubishi Chemical
Avanir Pharmaceuticals
Dong-A Pharmaceutical Co., Ltd.
Immune Pharmaceuticals
MediciNova
Sangamo BioSciences
LPI (LP Information)' newest research report, the “Diabetic Neurological Disorder Therapeutic Drug Industry Forecast” looks at past sales and reviews total world Diabetic Neurological Disorder Therapeutic Drug sales in 2022, providing a comprehensive analysis by region and market sector of projected Diabetic Neurological Disorder Therapeutic Drug sales for 2023 through 2029. With Diabetic Neurological Disorder Therapeutic Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Diabetic Neurological Disorder Therapeutic Drug industry.
This Insight Report provides a comprehensive analysis of the global Diabetic Neurological Disorder Therapeutic Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Diabetic Neurological Disorder Therapeutic Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Diabetic Neurological Disorder Therapeutic Drug market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Diabetic Neurological Disorder Therapeutic Drug and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Diabetic Neurological Disorder Therapeutic Drug.
The global Diabetic Neurological Disorder Therapeutic Drug market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Diabetic Neurological Disorder Therapeutic Drug is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Diabetic Neurological Disorder Therapeutic Drug is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Diabetic Neurological Disorder Therapeutic Drug is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Diabetic Neurological Disorder Therapeutic Drug players cover AstraZeneca, Johnson & Johnson, Takeda, Mitsubishi Chemical, Avanir Pharmaceuticals, Dong-A Pharmaceutical Co., Ltd., Immune Pharmaceuticals, MediciNova and Sangamo BioSciences, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Diabetic Neurological Disorder Therapeutic Drug market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Capsule
Pills
Other
Segmentation by application
Symmetrical Neuropathy
Focal and Multifocal Neuropathy
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
AstraZeneca
Johnson & Johnson
Takeda
Mitsubishi Chemical
Avanir Pharmaceuticals
Dong-A Pharmaceutical Co., Ltd.
Immune Pharmaceuticals
MediciNova
Sangamo BioSciences
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Diabetic Neurological Disorder Therapeutic Drug Market Size 2018-2029
2.1.2 Diabetic Neurological Disorder Therapeutic Drug Market Size CAGR by Region 2018 VS 2022 VS 2029
2.2 Diabetic Neurological Disorder Therapeutic Drug Segment by Type
2.2.1 Capsule
2.2.2 Pills
2.2.3 Other
2.3 Diabetic Neurological Disorder Therapeutic Drug Market Size by Type
2.3.1 Diabetic Neurological Disorder Therapeutic Drug Market Size CAGR by Type (2018 VS 2022 VS 2029)
2.3.2 Global Diabetic Neurological Disorder Therapeutic Drug Market Size Market Share by Type (2018-2023)
2.4 Diabetic Neurological Disorder Therapeutic Drug Segment by Application
2.4.1 Symmetrical Neuropathy
2.4.2 Focal and Multifocal Neuropathy
2.5 Diabetic Neurological Disorder Therapeutic Drug Market Size by Application
2.5.1 Diabetic Neurological Disorder Therapeutic Drug Market Size CAGR by Application (2018 VS 2022 VS 2029)
2.5.2 Global Diabetic Neurological Disorder Therapeutic Drug Market Size Market Share by Application (2018-2023)
3 Diabetic Neurological Disorder Therapeutic Drug Market Size by Player
3.1 Diabetic Neurological Disorder Therapeutic Drug Market Size Market Share by Players
3.1.1 Global Diabetic Neurological Disorder Therapeutic Drug Revenue by Players (2018-2023)
3.1.2 Global Diabetic Neurological Disorder Therapeutic Drug Revenue Market Share by Players (2018-2023)
3.2 Global Diabetic Neurological Disorder Therapeutic Drug Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Diabetic Neurological Disorder Therapeutic Drug by Regions
4.1 Diabetic Neurological Disorder Therapeutic Drug Market Size by Regions (2018-2023)
4.2 Americas Diabetic Neurological Disorder Therapeutic Drug Market Size Growth (2018-2023)
4.3 APAC Diabetic Neurological Disorder Therapeutic Drug Market Size Growth (2018-2023)
4.4 Europe Diabetic Neurological Disorder Therapeutic Drug Market Size Growth (2018-2023)
4.5 Middle East & Africa Diabetic Neurological Disorder Therapeutic Drug Market Size Growth (2018-2023)
5 Americas
5.1 Americas Diabetic Neurological Disorder Therapeutic Drug Market Size by Country (2018-2023)
5.2 Americas Diabetic Neurological Disorder Therapeutic Drug Market Size by Type (2018-2023)
5.3 Americas Diabetic Neurological Disorder Therapeutic Drug Market Size by Application (2018-2023)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Diabetic Neurological Disorder Therapeutic Drug Market Size by Region (2018-2023)
6.2 APAC Diabetic Neurological Disorder Therapeutic Drug Market Size by Type (2018-2023)
6.3 APAC Diabetic Neurological Disorder Therapeutic Drug Market Size by Application (2018-2023)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Diabetic Neurological Disorder Therapeutic Drug by Country (2018-2023)
7.2 Europe Diabetic Neurological Disorder Therapeutic Drug Market Size by Type (2018-2023)
7.3 Europe Diabetic Neurological Disorder Therapeutic Drug Market Size by Application (2018-2023)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Diabetic Neurological Disorder Therapeutic Drug by Region (2018-2023)
8.2 Middle East & Africa Diabetic Neurological Disorder Therapeutic Drug Market Size by Type (2018-2023)
8.3 Middle East & Africa Diabetic Neurological Disorder Therapeutic Drug Market Size by Application (2018-2023)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Diabetic Neurological Disorder Therapeutic Drug Market Forecast
10.1 Global Diabetic Neurological Disorder Therapeutic Drug Forecast by Regions (2024-2029)
10.1.1 Global Diabetic Neurological Disorder Therapeutic Drug Forecast by Regions (2024-2029)
10.1.2 Americas Diabetic Neurological Disorder Therapeutic Drug Forecast
10.1.3 APAC Diabetic Neurological Disorder Therapeutic Drug Forecast
10.1.4 Europe Diabetic Neurological Disorder Therapeutic Drug Forecast
10.1.5 Middle East & Africa Diabetic Neurological Disorder Therapeutic Drug Forecast
10.2 Americas Diabetic Neurological Disorder Therapeutic Drug Forecast by Country (2024-2029)
10.2.1 United States Diabetic Neurological Disorder Therapeutic Drug Market Forecast
10.2.2 Canada Diabetic Neurological Disorder Therapeutic Drug Market Forecast
10.2.3 Mexico Diabetic Neurological Disorder Therapeutic Drug Market Forecast
10.2.4 Brazil Diabetic Neurological Disorder Therapeutic Drug Market Forecast
10.3 APAC Diabetic Neurological Disorder Therapeutic Drug Forecast by Region (2024-2029)
10.3.1 China Diabetic Neurological Disorder Therapeutic Drug Market Forecast
10.3.2 Japan Diabetic Neurological Disorder Therapeutic Drug Market Forecast
10.3.3 Korea Diabetic Neurological Disorder Therapeutic Drug Market Forecast
10.3.4 Southeast Asia Diabetic Neurological Disorder Therapeutic Drug Market Forecast
10.3.5 India Diabetic Neurological Disorder Therapeutic Drug Market Forecast
10.3.6 Australia Diabetic Neurological Disorder Therapeutic Drug Market Forecast
10.4 Europe Diabetic Neurological Disorder Therapeutic Drug Forecast by Country (2024-2029)
10.4.1 Germany Diabetic Neurological Disorder Therapeutic Drug Market Forecast
10.4.2 France Diabetic Neurological Disorder Therapeutic Drug Market Forecast
10.4.3 UK Diabetic Neurological Disorder Therapeutic Drug Market Forecast
10.4.4 Italy Diabetic Neurological Disorder Therapeutic Drug Market Forecast
10.4.5 Russia Diabetic Neurological Disorder Therapeutic Drug Market Forecast
10.5 Middle East & Africa Diabetic Neurological Disorder Therapeutic Drug Forecast by Region (2024-2029)
10.5.1 Egypt Diabetic Neurological Disorder Therapeutic Drug Market Forecast
10.5.2 South Africa Diabetic Neurological Disorder Therapeutic Drug Market Forecast
10.5.3 Israel Diabetic Neurological Disorder Therapeutic Drug Market Forecast
10.5.4 Turkey Diabetic Neurological Disorder Therapeutic Drug Market Forecast
10.5.5 GCC Countries Diabetic Neurological Disorder Therapeutic Drug Market Forecast
10.6 Global Diabetic Neurological Disorder Therapeutic Drug Forecast by Type (2024-2029)
10.7 Global Diabetic Neurological Disorder Therapeutic Drug Forecast by Application (2024-2029)
11 Key Players Analysis
11.1 AstraZeneca
11.1.1 AstraZeneca Company Information
11.1.2 AstraZeneca Diabetic Neurological Disorder Therapeutic Drug Product Offered
11.1.3 AstraZeneca Diabetic Neurological Disorder Therapeutic Drug Revenue, Gross Margin and Market Share (2018-2023)
11.1.4 AstraZeneca Main Business Overview
11.1.5 AstraZeneca Latest Developments
11.2 Johnson & Johnson
11.2.1 Johnson & Johnson Company Information
11.2.2 Johnson & Johnson Diabetic Neurological Disorder Therapeutic Drug Product Offered
11.2.3 Johnson & Johnson Diabetic Neurological Disorder Therapeutic Drug Revenue, Gross Margin and Market Share (2018-2023)
11.2.4 Johnson & Johnson Main Business Overview
11.2.5 Johnson & Johnson Latest Developments
11.3 Takeda
11.3.1 Takeda Company Information
11.3.2 Takeda Diabetic Neurological Disorder Therapeutic Drug Product Offered
11.3.3 Takeda Diabetic Neurological Disorder Therapeutic Drug Revenue, Gross Margin and Market Share (2018-2023)
11.3.4 Takeda Main Business Overview
11.3.5 Takeda Latest Developments
11.4 Mitsubishi Chemical
11.4.1 Mitsubishi Chemical Company Information
11.4.2 Mitsubishi Chemical Diabetic Neurological Disorder Therapeutic Drug Product Offered
11.4.3 Mitsubishi Chemical Diabetic Neurological Disorder Therapeutic Drug Revenue, Gross Margin and Market Share (2018-2023)
11.4.4 Mitsubishi Chemical Main Business Overview
11.4.5 Mitsubishi Chemical Latest Developments
11.5 Avanir Pharmaceuticals
11.5.1 Avanir Pharmaceuticals Company Information
11.5.2 Avanir Pharmaceuticals Diabetic Neurological Disorder Therapeutic Drug Product Offered
11.5.3 Avanir Pharmaceuticals Diabetic Neurological Disorder Therapeutic Drug Revenue, Gross Margin and Market Share (2018-2023)
11.5.4 Avanir Pharmaceuticals Main Business Overview
11.5.5 Avanir Pharmaceuticals Latest Developments
11.6 Dong-A Pharmaceutical Co., Ltd.
11.6.1 Dong-A Pharmaceutical Co., Ltd. Company Information
11.6.2 Dong-A Pharmaceutical Co., Ltd. Diabetic Neurological Disorder Therapeutic Drug Product Offered
11.6.3 Dong-A Pharmaceutical Co., Ltd. Diabetic Neurological Disorder Therapeutic Drug Revenue, Gross Margin and Market Share (2018-2023)
11.6.4 Dong-A Pharmaceutical Co., Ltd. Main Business Overview
11.6.5 Dong-A Pharmaceutical Co., Ltd. Latest Developments
11.7 Immune Pharmaceuticals
11.7.1 Immune Pharmaceuticals Company Information
11.7.2 Immune Pharmaceuticals Diabetic Neurological Disorder Therapeutic Drug Product Offered
11.7.3 Immune Pharmaceuticals Diabetic Neurological Disorder Therapeutic Drug Revenue, Gross Margin and Market Share (2018-2023)
11.7.4 Immune Pharmaceuticals Main Business Overview
11.7.5 Immune Pharmaceuticals Latest Developments
11.8 MediciNova
11.8.1 MediciNova Company Information
11.8.2 MediciNova Diabetic Neurological Disorder Therapeutic Drug Product Offered
11.8.3 MediciNova Diabetic Neurological Disorder Therapeutic Drug Revenue, Gross Margin and Market Share (2018-2023)
11.8.4 MediciNova Main Business Overview
11.8.5 MediciNova Latest Developments
11.9 Sangamo BioSciences
11.9.1 Sangamo BioSciences Company Information
11.9.2 Sangamo BioSciences Diabetic Neurological Disorder Therapeutic Drug Product Offered
11.9.3 Sangamo BioSciences Diabetic Neurological Disorder Therapeutic Drug Revenue, Gross Margin and Market Share (2018-2023)
11.9.4 Sangamo BioSciences Main Business Overview
11.9.5 Sangamo BioSciences Latest Developments
12 Research Findings and Conclusion